Metformin Hydrochloride

Company announcement – No. 54 / 2026 Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes Petrelintide achieved up to 9.2% mean body weight reduction at week 28 versus 2.0% with placebo At week 28, petrelintide demonstrated a HbA1c reduction of up to 0.65% versus an increase of 0.23% with placebo Safety and tolerability pro petrelintide was consistent with that seen in the Phase 2 ZUPREME-1 trial Very low discontinuation rates due to gastrointestinal adverse events (1.9% for petrelintide versus 1.7% in placebo group) Data reinforce potential of petrelintide as a future first choice therapy for chronic weight management Copenhagen, Denmark, October 7, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced positive topline results from the Phase 2 ZUPREME-2 trial evaluating the efficacy and safety of petrelintide versus placebo in 220 people living with overweight or obesity and type 2 diabetes (mean baseline BMI of 36.3 kg/m 2 ; mean baseline HbA1c of 8.0%). The trial met its primary endpoint, demonstrating that once-weekly subcutaneous injections of petrelintide (escalated every fourth week) resulted in statistically significant and clinically meaningful reductions in body weight from baseline after 28 weeks in all three treatment arms compared to placebo. Study participants achieved up to 9.2% mean weight loss from baseline using the efficacy estimand (range across treatment arms: 7.4-9.2%), compared to 2.0% with placebo, with results remaining largely consistent under the treatment regimen estimand. Petrelintide also demonstrated clinically relevant reduction in HbA1c across all treatment arms with participants achieving a placebo-adjusted HbA1c reduction of 0.61%-0.88%. “These results further support the potential of petrelintide in chronic weight management and, for the first time, demonstrate its promise as a standalone treatment for those living with overweight or obesity and type 2 diabetes,” said David Kendall, MD, Chief Medical Officer at Zealand Pharma. “These data confirm the potential for clinically meaningful weight reduction with a promising and favorable tolerability profile. We are also encouraged by the improvements in glycemic control - a combination essential for supporting long-term, sustained benefits in people living with obesity and type 2 diabetes. Together with Roche, we look forward to investigating petrelintide in our recently initiated Phase 3 registrational program to address important unmet medical needs in chronic weight management.” No unexpected safety signals were observed with petrelintide treatment. Petrelintide demonstrated a favorable tolerability pro comparable to placebo. The treatment discontinuation rate due to gastrointestinal adverse events (AEs) was 1.9% for participants treated with petrelintide versus 1.7% with placebo. The most frequently reported AEs were gastrointestinal-related, the vast majority of which were mild and occurred during the escalation period. The safety and tolerability pro petrelintide observed in ZUPREME-2 confirms the findings of the 42-week Phase 2 ZUPREME-1 trial in people with overweight or obesity without type 2 diabetes. The full trial results from ZUPREME-2 are expected to be presented at an upcoming scientific conference. Zealand Pharma and Roche have started a Phase 3a program for petrelintide which consists of three trials: ZUPREME-3, ZUPREME-4, and ZUPREME-5, evaluating the efficacy and safety of once-weekly petrelintide versus placebo in people with obesity or overweight without type 2 diabetes, people with obesity or overweight with type 2 diabetes, and people with obesity or overweight and established cardiovascular disease, respectively. The three trials are expected to enroll approximately 7,000 participants in total and the first individuals have initiated treatment. For more information about the Phase 3 program, refer to Zealand Pharma Press Release no. 17 / 2026. This company announcement discloses inside information pursuant to Article 17 of the Market Abuse Regulation (EU) No 596/2014. About ZUPREME-2 ZUPREME-2 was a randomized, double-blind, placebo-controlled, parallel-group, multicenter, US-based Phase 2b clinical trial (NCT06926842). The trial compared three doses of once-weekly petrelintide with placebo, when added to a reduced-calorie diet and increased physical activity in participants with overweight or obesity and type 2 diabetes on metformin with or without an SGLT2 inhibitor. The trial included a screening period, a dose escalation treatment period up to 16 weeks with dose escalation every fourth week followed by a maintenance treatment period until week 28, and a follow-up period after treatment was completed until week 38. ZUPREME-2 enrolled a total of 220 participants in the United States. The primary endpoint in the trial is the percentage change in body weight from baseline to week 28. Secondary endpoints include, but are not limited to, body weight loss of ≥5% and ≥10%, absolute change in body weight, change in waist circumference, change in hemoglobin A1c (HbA1c), change in high-sensitivity C-reactive protein (hsCRP), change in fasting glucose, and change in fasting lipids. For more information about the ZUPREME-2 clinical trial of petrelintide, please visit . About petrelintide Petrelintide is a long-acting human amylin analog suitable for once-weekly subcutaneous administration that has been designed with chemical and physical stability with no fibrillation around neutral pH, allowing for co-formulation and co-administration with other peptides 1 . The hormone amylin is produced in the pancreatic beta cells and co-secreted with insulin in response to ingested nutrients. Amylin receptor activation has been shown to reduce body weight by restoring sensitivity to the satiety hormone leptin 2,3 , inducing a sense of feeling full faster. In 2025, Zealand Pharma and Roche entered into an exclusive collaboration and licensing agreement to co-develop and co-commercialize petrelintide for people living with overweight and obesity. Petrelintide is currently being developed for chronic weight management as both a monotherapy agent and in combination with Roche’s GLP-1/GIP receptor dual agonist enicepatide (CT-388). A Phase 2 trial evaluating the combination of petrelintide and enicepatide (CT-388) is planned for initiation in the second half of 2026. About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data‑driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma‑invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Cambridge, Massachusetts. Learn more at . Forward-looking statements This company announcement contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Pharma’s expectations or forecasts of future events regarding the research, development, and commercialization of pharmaceutical products, the timing of the company’s clinical trials and the reporting of data therefrom and the company’s significant events and potential catalysts in 2026 and financial guidance for 2026. These forward-looking statements may be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will,” “would”, and other words and terms of similar meaning. You should not place undue reliance on these statements, or the scientific data presented. The reader is cautioned not to rely on these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect, and which include, but are not limited to, unexpected costs or delays in clinical trials and other development activities due to adverse safety events or otherwise; unexpected concerns that may arise from additional data, analysis or results obtained during clinical trials; our ability to successfully market both new and existing products; changes in reimbursement rules and governmental laws and related interpretation thereof; government-mandated or market-driven price decreases for our products; introduction of competing products; production problems; unexpected growth in costs and expenses; our ability to effect the strategic reorganization of our businesses in the manner planned; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; regulatory authorities may require additional information or further studies, or may reject, fail to approve or may delay approval of our drug candidates or expansion of product labelling; failure to obtain regulatory approvals in other jurisdictions; exposure to product liability and other claims; interest rate and currency exchange rate fluctuations; unexpected contract breaches or terminations; inflationary pressures on the global economy; and political uncertainty. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. All such forward-looking statements speak only as of the date of this press release/company announcement and are based on information available to Zealand Pharma as of the date of this release/announcement. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice. Zealand Pharma® is a registered trademark of Zealand Pharma A/S. Contacts Eric Rojas (Investors) Vice President, Head of Investor Relations erojas@zealandpharma.com Neshat Anis Ahmadi (Investors) Manager, Investor Relations neahmadi@zealandpharma.com Rachel James-Owens (Media) Vice President, Corporate Communications & Media Relations Email: RJamesOwens@zealandpharma.com Andreas Hylleberg (Media) Director, External Communications Email: AHylleberg@zealandpharma.com Amber Fennell, Jessica Hodgson, Sean Leous (Media) ICR Healthcare Email: ZealandPharma@icrhealthcare.com +44 (0) 7739 658 783 Sources 1. Eriksson et al. Presentation at ObesityWeek, November 1–4, 2022, San Diego, CA. Link: . 2. Mathiesen et al. Eur J Endocrinol 2022;186(6):R93–R111. 3. Roth et al. Proc Natl Acad Sci U S A 2008;105(20):7257–7262. Attachment Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes

*本资料仅供医疗卫生专业人士参考，请勿向非医疗卫生专业人士发放 截至10月04日15点59分，近期共有 246 本期刊发布了 431 篇文章，其中血脂相关的文章共 37 篇，覆盖 17 个领域的内容。中国专家参与发表的文章有 18 篇。今日，影响因子最高的文章刊登在 Journal of environmental management (IF: 08.400) 期刊上。 今日头条 Headlines 01 JACC: Case reports 冠状动脉斑块脂质消退的“融化黄油征”：来自YELLOW III试验的启示 Keisuke Yasumura, Yuliya Vengrenyuk, Pruthvi C. Revaiah, Samin K. Sharma, Annapoorna S. Kini, etc. 脂质丰富的冠状动脉斑块与未来心血管事件相关。血管内近红外光谱（NIRS）通过脂质核心负荷指数定量脂质负荷，最大4mm节段脂质核心负荷指数（maxLCBI4mm）≥325可识别脂质丰富的高风险病变。系列冠状动脉内成像可在体内评估强化降脂治疗后的斑块改变，既往研究显示前蛋白转化酶枯草溶菌素/kexin 9型（PCSK9）抑制剂相关冠状动脉脂质负荷减少，主要见于长期随访。 在YELLOW III试验的这一报告中，我们强调了一种在慢性冠脉病中早期、视觉可识别的血管内成像模式，称为“融化黄油征”。 一名53岁男性因难治性心绞痛接受右冠状动脉慢性完全闭塞的经皮冠状动脉介入治疗。在YELLOW III试验的系列血管内成像方案中，对左回旋支中段的一个非靶、非限流性斑块进行了光学相干断层扫描（OCT）、NIRS和血管内超声（IVUS）检查。NIRS显示融合的黄色脂质信号，maxLCBI4mm为526，OCT对应薄纤维帽粥样硬化斑块，最小纤维帽厚度为60μm，符合高风险表型。IVUS斑块体积百分比为50.3%。尽管使用了最大耐受剂量他汀，低密度脂蛋白胆固醇为119 mg/dL。 在基线他汀治疗基础上加用依洛尤单抗，一种前蛋白转化酶枯草溶菌素/kexin 9型单克隆抗体，140mg每2周。26周时，匹配节段成像显示无血管造影进展，但近红外光谱显示脂质信号显著减弱，先前广泛脂质丰富区域仅残留小灶，产生类似融化黄油的外观，最大4mm节段脂质核心负荷指数降至227。光学相干断层扫描显示纤维帽同时增厚至80μm，而血管内超声斑块负荷保持不变。低密度脂蛋白胆固醇降至75 mg/dL。 “融化黄油征”代表了一种视觉可识别的NIRS斑块脂质消退模式，伴随OCT定义的纤维帽增厚，发生于短期PCSK9抑制后。这些早期成像变化提示慢性冠脉病中快速的体内斑块改善，并可能提供对不断演变范式的见解，即早期、目标导向的强化降脂治疗可能有利地改善非限流性高风险斑块，而对此类病变常规预防性支架的作用仍不确定。 本文由 韩玉莲 编辑 扫描二维码查看源文 JACC: Case reports | Ahead of Print. 10.1016/j.jaccas.2026.110611 02 Atherosclerosis Plus IF: 02.100 Lp(a)与首次ACS后早期LDL-C达标：一项真实世界队列研究 Núria Riera-Molist, Emma Puigoriol Juvanteny, Federico Swedzky, Ester Goutan-Roura, Nicolás José Fassano, Sílvia Montserrat Ortego, etc. 尽管强化降脂治疗，急性冠脉综合征（ACS）后早期达到指南推荐的低密度脂蛋白胆固醇（LDL-C）目标仍不理想。基线因素与早期LDL-C达标的关系尚不完全清楚，尤其是脂蛋白(a)[Lp(a)]的作用。本研究旨在评估首次ACS后早期LDL-C达标情况，并识别与达标相关的基线因素，重点关注Lp(a)。 研究为回顾性队列研究，连续纳入2025年1月至2026年4月期间因首次ACS住院并接受PCI的成人患者。主要终点为早期随访时达到指南推荐的LDL-C目标，定义为LDL-C<55 mg/dL且较基线降低≥50%。采用多变量逻辑回归评估临床变量与LDL-C达标之间的关联。 共纳入82例患者，其中70.7%为男性，37.2% Lp(a)水平升高。在中位随访5周（四分位距4-6周）时，31.7%的患者达到LDL-C目标，尽管出院时处方了高强度他汀治疗。在多变量模型中，低Lp(a)（比值比[OR] 8.72；95%置信区间[CI] 2.04-37.33）、当前吸烟（OR 5.29；95%CI 1.42-19.69）以及出院时在髙强度他汀治疗基础上使用依折麦布（OR 5.28；95%CI 1.31-21.32）与LDL-C达标相关。 结论认为，尽管常规处方高强度他汀治疗，首次ACS后早期LDL-C达标率仍然有限。Lp(a)升高与达到LDL-C目标的可能性降低相关。需要前瞻性研究来证实这些发现。 本文由 韩玉莲 编辑 扫描二维码查看源文 Atherosclerosis Plus | Volume 66, Issue 10.1016/j.athplu.2026.100618 03 Cardiology in Review IF: 02.300 血管内治疗对颅内动脉粥样硬化性与栓塞性大血管闭塞的有效性和安全性比较 FenFei Zeng, QiHong Pan, XuTao Wang, Zhen Wang, JiaYan Ni, etc. 本研究旨在评估血管内治疗对颅内动脉粥样硬化性大血管闭塞所致急性缺血性卒中的有效性和安全性，并与栓塞性大血管闭塞进行比较。 研究者对PubMed、Embase、Cochrane Library、万方数据和中国知网等数据库进行了广泛检索，检索时间截至2021年8月，采用自由词和主题词组合的检索策略。根据预定的纳入和排除标准进行文献筛选和数据提取，使用Review Manager 5.3进行所有统计学评价。 该荟萃分析共纳入14项研究，2748例患者。结果显示，与栓塞性大血管闭塞相比，颅内动脉粥样硬化性大血管闭塞患者接受血管内治疗后症状性颅内出血发生率显著更低。此外，颅内动脉粥样硬化性大血管闭塞组的补救治疗和支架植入率也显著低于栓塞性大血管闭塞组。 然而，两组在血管内治疗后的再通率、90天良好预后和死亡率方面相似。 研究表明，颅内动脉粥样硬化性大血管闭塞患者治疗后症状性颅内出血发生率低于栓塞性大血管闭塞患者。此外，颅内动脉粥样硬化性大血管闭塞患者在再通、90天良好预后和90天死亡率方面未表现出独特风险特征，导致与栓塞性大血管闭塞相似的结局。然而，颅内动脉粥样硬化性大血管闭塞患者中观察到更高比例的支架植入和补救治疗，这凸显了进一步研究颅内动脉粥样硬化性大血管闭塞血管内管理标准化的必要性。 本文由 韩玉莲 编辑 扫描二维码查看源文 Cardiology in Review | Volume 34, Issue 6, Page 465-579 10.1097/CRD.0000000000000830 04 Cardiovascular Therapeutics IF: 03.400 阿托伐他汀安全性再评估：从药物基因组学机制到个体化风险管理 Hanyu Wang, Yue Pan, Yiming Li, Pan Zhai, etc. 阿托伐他汀仍然是降脂治疗和心血管预防的基石，但对其不良反应的担忧持续影响患者的依从性和长期临床获益。 这篇结构化叙述性综述通过整合随机试验、荟萃分析、观察性研究、药物警戒分析、病例报告和临床前模型的证据，对其安全性特征进行了批判性再评估。证据根据研究设计进行解读，对照和合成的人类数据指导临床结论，较低级别的证据被视为支持性或假设生成性。 总体而言，阿托伐他汀提供了显著的心血管保护，而严重不良反应并不常见。主要的临床关注点包括他汀相关肌肉症状、肝脏实验室异常、药物相互作用，以及剂量和易感性依赖的新发糖尿病风险小幅增加。安全性受剂量、合并症、相互作用药物、药代动力学变异和转运体变异的影响，特别是SLCO1B1，尽管其他药物基因组标志物的临床可操作性仍然有限。 因此，作者强调个体化风险评估、相互作用审查、适当监测、停药和再激发、剂量调整、替代他汀以及必要时非他汀联合治疗。实验性递送系统和机制发现可能为未来策略提供信息，但尚未建立改善临床安全性的证据。综上所述，证据支持一个以获益为中心、证据分层的框架，该框架处理真实的毒性，而不夸大不确定的安全信号或不必要地停用有效治疗。 本文由 韩玉莲 编辑 扫描二维码查看源文 Cardiovascular Therapeutics | Volume 2026, Issue 1, Page 5568664-5568664 10.1155/cdr/4127131 中国发表（18） China Ultrasound in medicine & biology IF: 02.600Ahead of Print.No.01Automated Quantification of 3-D Carotid Ultrasound Vessel Wall Texture Change Predicts Vascular Events自动量化三维颈动脉超声血管壁纹理变化预测血管事件DOI: 10.1016/j.ultrasmedbio.2026.09.002 International immunopharmacology IF: 04.700Ahead of Print.No.02Chronic sleep deprivation promotes atherosclerosis via NFIL3/RORγt Axis mediated Th17/Treg imbalance, targeting IL-17A attenuates disease progression慢性睡眠剥夺通过NFIL3/RORγt轴介导的Th17/Treg失衡促进动脉粥样硬化，靶向IL-17A可减轻疾病进展DOI: 10.1016/j.intimp.2026.117496 iScience IF: 04.100Volume 29, Issue 10No.03Monotropein mitigates atherosclerotic plaque vulnerability through circ_0140736/miR-495/SIRPα-mediated efferocytosisMonotropein通过circ_0140736/miR-495/SIRPα介导的胞葬作用减轻动脉粥样硬化斑块易损性DOI: 10.1016/j.isci.2026.117439 FCVM IF: 02.900Volume 13, Issue No.04A guide to cell-type-specific Cre mouse models in atherosclerosis: from background strains to future directions动脉粥样硬化细胞类型特异性Cre小鼠模型指南：从背景品系到未来方向DOI: 10.3389/fcvm.2026.1905454 Free radical biology & medicine IF: 08.200Ahead of Print.No.05Coordinated Retinal Metabolic Remodeling Reveals Mitochondrial Stress and Redox Vulnerability in Experimental Myopia协调性视网膜代谢重塑揭示实验性近视中的线粒体应激与氧化还原脆弱性DOI: 10.1016/j.freeradbiomed.2026.09.024 Frontiers in endocrinology IF: 04.600Volume 17, Issue No.06Association between glycometabolic indicators and risk of early vascular aging and their predictive value糖代谢指标与早期血管老化风险之间的关联及其预测价值DOI: 10.3389/fendo.2026.1946806 J Physiol Biochem IF: 04.300Volume 82, Issue 1No.07Programmed cell death protein 4 (PDCD4): a pleiotropic regulator in cardiovascular diseases程序性细胞死亡蛋白4（PDCD4）：心血管疾病中的多效性调节因子DOI: 10.1007/s13105-026-01237-4 FCVM IF: 02.900Volume 13, Issue No.08Pharmacogenomics-guided therapy for essential hypertension: a multi-center randomized controlled open-label trial药物基因组学指导的原发性高血压治疗：一项多中心随机对照开放标签试验DOI: 10.3389/fcvm.2026.1842597 Diabetes Res Clin Pract IF: 07.400Ahead of Print.No.09Effects of corn-derived dietary fibers on cardiometabolic risk factors: a systematic review and meta-analysis of randomized controlled trials玉米来源膳食纤维对心血管代谢危险因素的影响：随机对照试验的系统综述和荟萃分析DOI: 10.1016/j.diabres.2026.113588 J Environ Manage IF: 08.400Ahead of Print.No.10Informing pharmaceutical regulation in China: Risk-based priority ranking across nine river basins为中国药品监管提供依据：基于风险的九大流域优先排序DOI: 10.1016/j.jenvman.2026.131070 Frontiers in public health IF: 03.400Volume 14, Issue No.11Nonlinear relationship between triglyceride glucose-body mass index and the risk of prediabetes: a multi-center retrospective cohort study甘油三酯葡萄糖-体重指数与糖尿病前期风险之间的非线性关系：一项多中心回顾性队列研究DOI: 10.3389/fpubh.2026.1916726 Journal of inflammation research IF: 04.100Volume 19, Issue No.121H NMR-Based Metabolomics Coupled With Molecular Docking to Explore the Anti-NAFLD Effects of Astragalus Radix and Dioscoreae Rhizoma Herb Pair基于1H NMR代谢组学结合分子对接探索黄芪-山药药对抗非酒精性脂肪性肝病作用DOI: 10.2147/JIR.S618546 Frontiers in endocrinology IF: 04.600Volume 17, Issue No.13Comparative associations of cumulative cholesterol-HDL-glucose index and triglyceride-glucose index with risk of cardiovascular disease in individuals with cardiovascular-kidney-metabolic syndrome stages 0-3: a prospective cohort study累积胆固醇-高密度脂蛋白-葡萄糖指数与甘油三酯-葡萄糖指数对心血管-肾脏-代谢综合征0-3期人群心血管疾病风险的比较关联：一项前瞻性队列研究DOI: 10.3389/fendo.2026.1950124 Frontiers in endocrinology IF: 04.600Volume 17, Issue No.14Clinical and metabolic links between hypothyroidism and metabolic syndrome: a review甲状腺功能减退症与代谢综合征之间的临床与代谢联系：综述DOI: 10.3389/fendo.2026.1890732 FCVM IF: 02.900Volume 13, Issue No.15Advancing precision cardio-oncology: multimodal surveillance and stratified management of immunotherapy-induced cardiovascular toxicity推进精准肿瘤心脏病学：免疫治疗相关心血管毒性的多模态监测与分层管理DOI: 10.3389/fcvm.2026.1891563 Int J Numer Method Biomed Eng IF: 02.400Volume 42, Issue 10No.16Quadtree SBFEM and MSPM Based Uncertain Damage Analysis With Random Field Model for Soft Biological Tissues基于四叉树SBFEM和MSPM的软组织随机场不确定性损伤分析DOI: 10.1002/cnm.70221 Cardiovascular Therapeutics IF: 03.400Volume 2026, Issue 1, Page 5568664-5568664No.17Atorvastatin Safety Reappraised: From Pharmacogenomic Mechanisms to Personalized Risk Management阿托伐他汀安全性再评估：从药物基因组学机制到个体化风险管理DOI: 10.1155/cdr/4127131 The FASEB journal : IF: 04.200Volume 40, Issue 19No.18Akkermansia muciniphila HHAKKα Prevents High-Fat Diet-Induced Obesity in Mice via Gut Microbiota Modulation and Regulation of Hepatic Lipid MetabolismAkkermansia muciniphila HHAKKα通过调节肠道微生物群和肝脏脂质代谢预防高脂饮食诱导的小鼠肥胖DOI: 10.1096/fj.202603191RR 其他发布内容（16） More Published Articles JVIR IF: 02.600Ahead of Print.No.01Wireless Tenzing Crossing of Large Vessel-Occlusions - Feasibility of a Technique After Failed Stroke Thrombectomy with Traditional Approaches无线Tenzing穿越大血管闭塞——传统方法卒中取栓失败后技术的可行性DOI: 10.1016/j.jvir.2026.109109 Clinical rheumatology IF: 02.800Ahead of Print.No.02Neutrophil extracellular trap suppression in rheumatoid arthritis patients treated with biologic therapy: a prospective observational study生物制剂治疗类风湿关节炎患者中中性粒细胞胞外诱捕网的抑制：一项前瞻性观察性研究DOI: 10.1007/s10067-026-08454-8 J Am Nutr Assoc IF: 02.600Ahead of Print.No.03Mediterranean Diet, Physical Activity, and Metabolic Syndrome in Breast Cancer Survivors on Adjuvant Endocrine Therapy: A Cross-Sectional Study From North Africa地中海饮食、体力活动与接受辅助内分泌治疗的乳腺癌生存者代谢综合征：一项来自北非的横断面研究DOI: 10.1080/27697061.2026.2731004 Eur J Intern Med IF: 06.100Ahead of Print.No.04Statins are associated with decreased risk of disease progression and death in non-cirrhotic patients with primary biliary cholangitis他汀类药物与降低非肝硬化原发性胆汁性胆管炎患者的疾病进展和死亡风险相关DOI: 10.1016/j.ejim.2026.107219 Curēus IF: 01.300Volume 18, Issue 9No.05Association of Poststroke Pain Prevalence and Subtypes With Lesion Sites in Ischemic and Hemorrhagic Stroke: A Cross-Sectional Study缺血性和出血性卒中后疼痛患病率及亚型与病灶部位的关联：一项横断面研究DOI: 10.7759/cureus.115624 Avicenna J Med BiotechnolVolume 18, Issue 3No.06Antidiabetic Effects of Ethanolic Extract of Macrothelypteris torresiana : In Vitro Enzyme Inhibition and In Vivo Evaluation in Streptozotocin-Induced Sprague-Dawley Rats毛蕨乙醇提取物的抗糖尿病作用：体外酶抑制及链脲佐菌素诱导Sprague-Dawley大鼠体内评价DOI: 10.18502/ajmb.v18i3.22241 Clinical oral investigations IF: 03.100Volume 30, Issue 10No.07Detection of serum amyloid A in Saliva of patients with internal carotid artery stenosis: a pilot study颈内动脉狭窄患者唾液中血清淀粉样蛋白A的检测：一项初步研究DOI: 10.1007/s00784-026-07202-1 Current rheumatology reports IF: 03.900Volume 28, Issue 1No.08Seronegative Immune-Mediated Necrotizing Myopathy: An Overview for Optimal Clinical Management血清阴性免疫介导坏死性肌病：优化临床管理概述DOI: 10.1007/s11926-026-01238-8 Frontiers in neurology IF: 02.800Volume 17, Issue No.09A systematic review of intracranial atherosclerosis epidemiology-the largest contributor to the global ischemic stroke burden?颅内动脉粥样硬化流行病学系统综述——全球缺血性卒中负担的最大贡献者？DOI: 10.3389/fneur.2026.1866302 Drug Des Devel Ther IF: 05.100Volume 20, Issue No.10Amorphous Solid Dispersions for BCS Class II Antihyperlipidemic Drugs: From Drug-Polymer Interactions to in vivo PerformanceBCS II类抗高脂血症药物的无定形固体分散体：从药物-聚合物相互作用到体内性能DOI: 10.2147/DDDT.S634131 FCVM IF: 02.900Volume 13, Issue No.11Apolipoprotein E ε3/ε4 and coronary artery disease: lipid and non-lipid mechanisms in personalized prevention - narrative review载脂蛋白E ε3/ε4与冠状动脉疾病：个体化预防中的脂质与非脂质机制——叙述性综述DOI: 10.3389/fcvm.2026.1885898 Epileptic disorders IF: 02.700Ahead of Print.No.12The effect of anti-seizure medications on exposure to statins: A systematic review and meta-analysis抗癫痫发作药物对他汀类药物暴露的影响：系统评价与荟萃分析DOI: 10.1002/epd2.70416 Scientific reports IF: 03.900Volume 16, Issue 1No.13A specialized cardiological outpatient clinic for patients with psoriasis: results from a single-center pilot study针对银屑病患者的专科心脏门诊：单中心试点研究结果DOI: 10.1038/s41598-026-72219-1 BMC pregnancy and childbirth IF: 02.700Volume 26, Issue 1No.14Comparative effectiveness of statins, metformin, and vitamin D, for prevention of preeclampsia: a systematic review and network meta-analysis of randomized trials他汀类药物、二甲双胍和维生素D预防子痫前期的比较效果：随机试验的系统评价和网络Meta分析DOI: 10.1186/s12884-026-09920-6 AAPS PharmSciTech IF: 04.000Volume 27, Issue 7No.15Glutamine-tagged Sorafenib and Atorvastatin Coloaded Polymeric Nanoparticles for Hybrid Cell Death Induction in Colorectal Cancer: Part I Formulation, Characterization, In-vitro/In-vivo Safety and Efficacy Evaluation谷氨酰胺标记的索拉非尼和阿托伐他汀共载聚合物纳米粒用于结直肠癌混合细胞死亡诱导：第一部分 制剂、表征、体外/体内安全性和有效性评价DOI: 10.1208/s12249-026-03546-9 Cardio-Oncology IF: 03.200Volume 12, Issue 1No.16Long-term outcomes of prophylactic cardioprotection in early-stage breast cancer patients on non-anthracycline anti-HER2 therapy非蒽环类抗HER2治疗的早期乳腺癌患者预防性心脏保护的长期结局DOI: 10.1186/s40959-026-00581-0 16 Atherosclerosis(AS) 动脉粥样硬化 11 Triglycerides(TG) 甘油三酯 8 Statins 他汀 3 Dyslipidemias 血脂异常 3 Atorvastatin 阿托伐他汀 3 Total Cholesterol(TC) 总胆固醇 2 Simvastatin 辛伐他汀 2 Hyperlipidemias 高脂血症 2 Ezetimibe 依折麦布 1 Gemfibrozil 吉非罗齐 1 Lipoprotein(a)(Lp(a)) 脂蛋白a 1 Lovastatin 洛伐他汀 1 Evolocumab 依洛尤单抗 1 Rosuvastatin 瑞舒伐他汀 1 Pravastatin 普伐他汀 1 Apolipoprotein B(ApoB) 载脂蛋白B 1 Fibric Acids 贝特类 编辑：韩玉莲 审校：韩玉莲